MUC1 and neoplasm: In 2023, alternative Mincle-targeting–TAA conjugates were prepared containing the MUC1 tumour-associated antigen and the Mincle-targeting agonist GlcC14C18 (13c) [33], which was appended to the MUC1 peptide via a PEG-functionalised cyclobutadione linker either via an α- or β-linkage (37a and 37b, respectively) [247].